AI Article Synopsis
- The MTT assay evaluated how pamidronate, clodronate, and mevastatin affect the viability of various Ewing's sarcoma cell lines.
- Pamidronate was particularly effective, significantly reducing cell viability by up to 80% after 72 hours at a concentration of 50 microM, while its analog had no effect.
- Clodronate also reduced cell viability but only by about 40% at 1 mM, indicating that pamidronate could be a promising candidate for future Ewing's sarcoma treatments.
Article Abstract
The MTT assay was used to measure the effects of pamidronate, clodronate and mevastatin on the cell viability of Ewing's sarcoma cell lines 6647, CADO-ES-1, ES-2, ES-3, RD-ES, SK-ES-1, STA-ET-2.1 and VH-64. Treatment of these cells with pamidronate inhibited cell viability in a time- and dose-dependent manner. After a 72-h incubation period with 50 microM pamidronate, cell numbers were reduced by up to 80%, whereas the monophosphonate analog 3-aminopropyl phosphonate had no effect at concentrations up to 2 mM. Clodronate reduced cell viability by maximally 40% at 1 mM. These data provide the first evidence for a direct growth-inhibitory effect of pamidronate on Ewing's sarcoma cells. Hence, pamidronate definitely merits a more thorough exploration into its potential use in the therapy of patients with Ewing's sarcoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00001813-200310000-00013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!